Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants David Saxon - Needham & Company James Beers - William Blair Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2024 Earnings Res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 80-0625749 (State or other jurisdiction of ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Tom Stephan - Stifel David Saxon - Needham & Company Margaret Kaczor - William Blair Operator Ladies and gentlemen, thank you for standing by and welcome to the ...

Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance MENLO PARK, Calif., March 7, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended Decem ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2023 was $20 million, representing a 7% growth compared to Q3 2022, at the top end of the guidance range [51] - Surgical Glaucoma revenues were $18.4 million, up 8% year-over-year, with over 1,100 customers ordering products, a 16% increase from the previous year [51] - Dry Eye revenues were $1.6 million, down 1% year-over-year and down 24% from Q2 2023, attributed to a shift in commercial strategy [54] - Gross margin improved to 86.6% from 84.3% year-over-year, driven by manufacturing efficiencies and higher average selling prices [56] - Total operating expenses decreased by 18% to $30.7 million compared to Q3 2022, with adjusted operating expenses at $26.8 million [57] - Net loss for the quarter was $13 million, or $0.27 per share, compared to a net loss of $22.2 million, or $0.46 per share, in Q3 2022 [60] Business Line Data and Key Metrics Changes - Surgical Glaucoma segment showed strong customer retention but experienced lower utilization and new account additions due to reimbursement uncertainties [52] - Dry Eye segment had 318 active customers, a 40% increase year-over-year, but total revenue declined due to fewer new customers [55] Market Data and Key Metrics Changes - The company faced challenges in the reimbursement environment, particularly with the final LCD published by WPS, which limited coverage for certain procedures [23][24] - The uncertainty in reimbursement affected utilization across all geographic regions, with a more pronounced impact in areas covered by the five MACs [53] Company Strategy and Development Direction - The company is focused on maintaining and enhancing market access for its technologies, particularly for the Surgical Glaucoma products [22] - A restructuring plan was implemented to reduce operating expenses and improve efficiencies, including a 10% reduction in headcount [47] - The company is actively pursuing new procedure codes with CMS to enhance reimbursement for its technologies [27][35] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with the final LCD from WPS and is working to prevent its implementation [23][29] - The company is optimistic about the support from the surgical community and is focused on addressing the LCD issues [73] - Future cash restructuring charges of approximately $1.3 million are expected in Q4 2023 due to the reduction in force [62] Other Important Information - The company withdrew its full-year 2023 revenue and adjusted operating expense guidance due to reimbursement uncertainties [61] - The GEMINI 2 study results are expected to be published soon, which may support the case for continued coverage of OMNI technology [26] Q&A Session Summary Question: Discussions with customers regarding WPS update - Management noted that most surgeons are still trying to understand the implications of the LCD and expressed disappointment over the lack of coverage for canaloplasty [71] Question: Steps to remediate current ruling with WPS - The company is engaging with multiple stakeholders, including MACs and national societies, to address the LCD issues and gather support [82] Question: Timeline for LCD reconsideration process - The reconsideration process can take several months and cannot be initiated until the LCD is effective, which is set for December 24 [92]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (Sta ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Philip Tailor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Craig Bijou - Bank of America Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2023 Earnings Conference Call. At this time, all parti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (St ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Phillip Dantoin - Piper Sandler Thomas Stephan - Stifel Michael Arens - William Blair Operator Good day and thank you for standing by. Welcome to the Sight Sciences First Quarter 2023 Earnings Results Cal ...